These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 18057668)

  • 21. Skeletal complications of rheumatoid arthritis.
    Heinlen L; Humphrey MB
    Osteoporos Int; 2017 Oct; 28(10):2801-2812. PubMed ID: 28779302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bone safety of low-dose glucocorticoids in rheumatic diseases.
    Saag KG
    Ann N Y Acad Sci; 2014 May; 1318():55-64. PubMed ID: 24815076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Bone destruction and bone loss in rheumatoid arthritis--mechanism, prevention and treatment].
    Suzuki Y; Ide M; Uehara R; Itoh G
    Nihon Rinsho; 2002 Mar; 60 Suppl 3():407-17. PubMed ID: 11979937
    [No Abstract]   [Full Text] [Related]  

  • 24. Inflammation-induced bone loss: can it be prevented?
    Romas E; Gillespie MT
    Rheum Dis Clin North Am; 2006 Nov; 32(4):759-73. PubMed ID: 17288976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rheumatoid arthritis and periodontitis: biological links and the emergence of dual purpose therapies.
    Modi DK; Chopra VS; Bhau U
    Indian J Dent Res; 2009; 20(1):86-90. PubMed ID: 19336867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates.
    Romas E
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):1065-79. PubMed ID: 16301197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bisphosphonates in multiple myeloma: a fractured consensus.
    Kumar SK
    Leuk Lymphoma; 2015 Mar; 56(3):553-4. PubMed ID: 25224456
    [No Abstract]   [Full Text] [Related]  

  • 28. Bisphosphonate-osteoclasts: changes in osteoclast morphology and function induced by antiresorptive nitrogen-containing bisphosphonate treatment in osteoporosis patients.
    Jobke B; Milovanovic P; Amling M; Busse B
    Bone; 2014 Feb; 59():37-43. PubMed ID: 24211427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteoporosis in patients with rheumatoid arthritis: an update in epidemiology, pathogenesis, and fracture prevention.
    Raterman HG; Bultink IE; Lems WF
    Expert Opin Pharmacother; 2020 Oct; 21(14):1725-1737. PubMed ID: 32605401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial.
    Jensen TW; Hansen MS; Hørslev-Petersen K; Hyldstrup L; Abrahamsen B; Langdahl B; Zerahn B; Pødenphant J; Stengaard-Petersen K; Junker P; Østergaard M; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen AJ; Tarp U; Lindegaard H; Jurik AG; Vestergaard A; Hetland ML;
    Ann Rheum Dis; 2014 Jun; 73(6):1123-9. PubMed ID: 23661492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of antiresorptive and bone forming treatments in bone erosions in rheumatoid arthritis.
    Azuaga-Piñango AB; Peris P
    Med Clin (Barc); 2020 May; 154(9):358-365. PubMed ID: 32113698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Bone targeting agents: bisphosphonates].
    Debiais F
    Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamics of bisphosphonates in arthritis.
    Le Goff B; Heymann D
    Expert Rev Clin Pharmacol; 2011 Sep; 4(5):633-41. PubMed ID: 22220307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the selective glucocorticoid receptor modulator compound A on bone metabolism and inflammation in male mice with collagen-induced arthritis.
    Rauner M; Thiele S; Sinningen K; Winzer M; Salbach-Hirsch J; Gloe I; Peschke K; Haegeman G; Tuckermann JP; Hofbauer LC
    Endocrinology; 2013 Oct; 154(10):3719-28. PubMed ID: 23885015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging anti-osteoclast therapy for rheumatoid arthritis.
    Tanaka S
    J Orthop Sci; 2018 Sep; 23(5):717-721. PubMed ID: 30075997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion.
    O'Gradaigh D; Compston JE
    Rheumatology (Oxford); 2004 Feb; 43(2):122-30. PubMed ID: 12867576
    [No Abstract]   [Full Text] [Related]  

  • 38. Inhibition of osteoclasts does not prevent joint ankylosis in a mouse model of spondyloarthritis.
    Lories RJ; Derese I; Luyten FP
    Rheumatology (Oxford); 2008 May; 47(5):605-8. PubMed ID: 18334523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis.
    Sims NA; Green JR; Glatt M; Schlict S; Martin TJ; Gillespie MT; Romas E
    Arthritis Rheum; 2004 Jul; 50(7):2338-46. PubMed ID: 15248235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic intervention of rheumatoid arthritis bone loss].
    Ono K; Ohashi S; Tanaka S
    Clin Calcium; 2013 Sep; 23(9):1345-52. PubMed ID: 23999372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.